Micell Technologies is bringing together the clinical advantages of a drug-eluting stent with the long-term safety and stability of a bare metal stent. The resulting drug-delivery device is intended to redefine the field of interventional cardiology. Read more.

September 21, 2009 — Micell Receives $15 Million Equity Investment.
Read more.

March 4, 2009 — The Micell Rapid Absorption Polymer DES System to be presented at CRT 2009.
Read more.